安罗替尼联合PD-1抑制剂治疗广泛期小细胞肺癌的疗效及安全性  

Efficacy and safety of Anlotinib combined with PD⁃1 blockades for extensive⁃stage small⁃cell lung cancer

作　　者：李建国[1] 李树满[1] 陈辉[2] LI Jianguo;LI Shuman;CHEN Hui(Surgery Department,Tianjin Beichen Hospital,Tianjin 300400,China)

机构地区：[1]天津市北辰医院外科,天津300400 [2]天津医科大学肿瘤医院肺部肿瘤科,天津300060

出　　处：《实用医学杂志》2023年第17期2248-2252,共5页The Journal of Practical Medicine

基　　金：吴阶平医学基金会临床科研专项资助基金(课题编号:320675017287)。

摘　　要：目的 本研究旨在探索安罗替尼联合PD-1单抗治疗广泛期小细胞肺癌患者的疗效和安全性。方法 本研究回顾性分析了36例既往至少接受过一种系统化疗方案治疗的广泛期SCLC患者,所有患者均接受了安罗替尼联合PD-1单抗的治疗。结果 36例SCLC患者均可进行疗效和安全性分析,最佳疗效结果显示客观缓解率为27.8%(95%CI:14.2%~45.2%),疾病控制率为80.6%(95%CI:64.0%~91.8%)。无进展生存期(PFS)和中位点生存期(OS)分别为4.6个月(95%CI:3.1~6.1)和9.3个月(95%CI:3.3~15.3),总体不良反应安全可控。Cox回归分析提示ECOG体质状况评分是PFS的独立影响因素。结论 真实世界中安罗替尼联合PD-1单抗治疗广泛期SCLC患者具有初步的疗效和可控的安全性。Objective To investigate the efficacy and safety of Anlotinib combined with PD-1 blockades in patients with extensive-stage small-cell lung cancer(ES-SCLC).Methods This study retrospectively analyzed the data of 36 patients with ES-SCLC who were treated with at least one previous systematic chemotherapy regimen.All the patients received Anlotinib plus PD-1 blockades therapy.Results Efficacy evaluation and safety analysis were conducted in all the patients.The best efficacy results showed objective response rate was 27.8%(95%CI:14.2%~45.2%);disease control rate 80.6%(95%CI:64.0%~91.8%).The PFS and OS of the 36 patients were 4.6 months(95%CI:3.1~6.1)and 9.3 months(95%CI:3.3~15.3),respectively,indicating that overall adverse reactions were tolerate and controllable.Multivariate cox regression analysis for PFS indicated that ECOG performance status was the independent factor to predict PFS.Conclusion Anlotinib combined with PD-1 block⁃ades regimen preliminarily demonstrates encouraging efficacy and tolerable safety for patients with ES-SCLC in realworld clinical practice.

关 键 词：小细胞肺癌 安罗替尼 PD-1抑制剂 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]